Abstract
Objective To investigate the infection characteristics and drug resistance of methicillin resistant Staphylococcus aureus after liver transplantation. Methods Retrospectively analyzed the clinical data of 170 patients who underwent liver transplantation in Beijing Chaoyang Hospital, Capital Medical University between January 2011 and April 2016. The incidence, pathogenic characteristics, distribution and drug resistance of methicillin resistant Staphylococcus aureus were analyzed. Results In this research, the methicillin resistant Staphylococcus aureus infection occurred in 23 cases after liver transplantation, and the incidence rate was 13.53%(23/170). There were 27 strains of pathogens had been isolated, and 74.07%(20/27) of pathogens were isolated from peritoneal drainage fluid. The most common methicillin resistant Staphylococcus aureus were Staphylococcus haemolyticus, Staphylococcus epidermidis and Staphylococcus hominis, accounting for 29.63%(8/27), 22.22%(6/27) and 14.81%(4/27). Drug sensitivity results indicated that the methicillin resistant Staphylococcus aureus were completely resistant to Penicillin, Oxacillin and Methicillin antibiotics. And the pathogens were extensively drug-resistant to Ciprofloxacin, Levofloxacin and Moxifloxacin, the resistance rates were 63%(15/24), 63%(15/24) and 58%(14/24). But the pathogens were sensitive to Teicoplanin, Vancomycin and Linezolid, and there have not been detected drug-resistant bacteria. Conclusions The infection of methicillin resistant Staphylococcus aureus is one of the most common pathogens after liver transplantation. Routine prophylactic antibiotics are not useful for the treatment, however, Teicoplanin, Vancomycin and Linezolid can be used as the first choice of treatment. Key words: Liver transplantation; Methicillin-resistant Staphylococcus aureus; Pathogenic bacteria; Drug resistance
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.